Us Congress 2023-2024 Regular Session

Us Congress Senate Bill SB2922 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	II
2	2	118THCONGRESS
3	3	1
4	4	STSESSION S. 2922
5	5	To advance population research for chronic pain.
6	6	IN THE SENATE OF THE UNITED STATES
7	7	SEPTEMBER26 (legislative day, SEPTEMBER22), 2023
8	8	Mr. C
9	9	ASEY(for himself, Mrs. BLACKBURN, Mr. KAINE, and Mr. CRAMER) in-
10	10	troduced the following bill; which was read twice and referred to the Com-
11	11	mittee on Health, Education, Labor, and Pensions
12	12	A BILL
13	13	To advance population research for chronic pain.
14	14	Be it enacted by the Senate and House of Representa-1
15	15	tives of the United States of America in Congress assembled, 2
16	16	SECTION 1. SHORT TITLE. 3
17	17	This Act may be cited as the ‘‘Advancing Research 4
18	18	for Chronic Pain Act of 2023’’. 5
19	19	SEC. 2. NATIONAL CHRONIC PAIN INFORMATION SYSTEM. 6
20	20	Part P of title III of the Public Health Service Act 7
21	21	(42 U.S.C. 280g et seq.) is amended by adding at the end 8
22	22	the following: 9
23	23	VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\S2922.IS S2922
24	24	kjohnson on DSK7ZCZBW3PROD with $$_JOB 2
25	25	•S 2922 IS
26	26	‘‘SEC. 399V–8. CHRONIC PAIN RESEARCH. 1
27	27	‘‘(a) I
28	28	NGENERAL.—The Secretary, acting through 2
29	29	the Director of the Centers for Disease Control and Pre-3
30	30	vention in consultation with the Director of the National 4
31	31	Center for Injury Prevention and Control and the Director 5
32	32	of the National Center for Chronic Disease Prevention and 6
33	33	Health Promotion, and in coordination with the NIH 7
34	34	Helping to End Addiction Long-term Initiative and with 8
35	35	other agencies as the Secretary determines appropriate, 9
36	36	shall— 10
37	37	‘‘(1) utilize available Federal research data to 11
38	38	clarify the incidence and prevalence of chronic pain 12
39	39	from any source, including injuries, operations, and 13
40	40	diseases and conditions; 14
41	41	‘‘(2) identify gaps in the available research data 15
42	42	and collect deidentified population research data 16
43	43	using medical claims and survey data to fill gaps in 17
44	44	available research data, such as information con-18
45	45	cerning— 19
46	46	‘‘(A) incidence and prevalence of specific 20
47	47	pain conditions; 21
48	48	‘‘(B) demographics and other information, 22
49	49	such as age, race, ethnicity, gender, and geo-23
50	50	graphic location; 24
51	51	‘‘(C) the incidence and prevalence of 25
52	52	known chronic pain conditions, as well as of 26
53	53	VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S2922.IS S2922
54	54	kjohnson on DSK7ZCZBW3PROD with $$_JOB 3
55	55	•S 2922 IS
56	56	diseases and conditions that include or lead to 1
57	57	pain; 2
58	58	‘‘(D) risk factors that may be associated 3
59	59	with chronic pain conditions, such as genetic 4
60	60	and environmental risk factors and other infor-5
61	61	mation, as appropriate; 6
62	62	‘‘(E) diagnosis and progression markers; 7
63	63	‘‘(F) both direct and indirect costs of ill-8
64	64	ness; 9
65	65	‘‘(G) the epidemiology of the conditions; 10
66	66	‘‘(H) the detection, management, and 11
67	67	treatment of the conditions; 12
68	68	‘‘(I) the epidemiology, detection, manage-13
69	69	ment, and treatment of frequent secondary or 14
70	70	co-occurring conditions, such as depressive, anx-15
71	71	iety, and substance use disorders; 16
72	72	‘‘(J) the utilization of medical and social 17
73	73	services by patients with chronic pain condi-18
74	74	tions, including the direct health care costs of 19
75	75	pain treatment, both traditional and alternative, 20
76	76	and the indirect costs (such as missed work, 21
77	77	public and private disability, and reduction in 22
78	78	productivity); and 23
79	79	VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\S2922.IS S2922
80	80	kjohnson on DSK7ZCZBW3PROD with $$_JOB 4
81	81	•S 2922 IS
82	82	‘‘(K) the effectiveness of evidence-based 1
83	83	treatment approaches on chronic pain condi-2
84	84	tions; 3
85	85	‘‘(3) develop, in collaboration with individuals 4
86	86	and organizations with appropriate chronic pain ex-5
87	87	pertise, including patients or patient advocates, epi-6
88	88	demiologists, representatives of national voluntary 7
89	89	health associations, health information technology 8
90	90	experts, clinicians, and research scientists, standard 9
91	91	definitions and approaches for population research 10
92	92	on chronic pain to efficiently promote greater com-11
93	93	parability of data; and 12
94	94	‘‘(4) disseminate, pursuant to the public 13
95	95	webpage under subsection (b), and, as appropriate, 14
96	96	to the public and to other Federal departments and 15
97	97	agencies, any findings, developed population research 16
98	98	standards, and available Federal data sources re-17
99	99	lated to chronic pain. 18
100	100	‘‘(b) D
101	101	ISSEMINATION.—The Secretary, acting 19
102	102	through the Director of the Centers for Disease Control 20
103	103	and Prevention, shall establish a public webpage, to be 21
104	104	known as the Chronic Pain Information Hub, that— 22
105	105	‘‘(1) aggregates and summarizes available Fed-23
106	106	eral data sources, indicators, and peer-reviewed re-24
107	107	search related to chronic pain; 25
108	108	VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\S2922.IS S2922
109	109	kjohnson on DSK7ZCZBW3PROD with $$_JOB 5
110	110	•S 2922 IS
111	111	‘‘(2) includes an up-to-date summary of com-1
112	112	plete, underway, and planned data collection and 2
113	113	analysis related to chronic pain that is conducted 3
114	114	and supported by the Centers for Disease Control 4
115	115	and Prevention; and 5
116	116	‘‘(3) translates research findings into clinical 6
117	117	tools and resources, recommendations for closing re-7
118	118	search gaps, and recommendations for population re-8
119	119	search standards for researchers, with recommenda-9
120	120	tions updated annually to incorporate research find-10
121	121	ings from the prior year. 11
122	122	‘‘(c) C
123	123	ONFLICTS OFINTEREST.—If an individual or 12
124	124	organization that collaborates with the Secretary in car-13
125	125	rying out subsection (a) receives a payment or other trans-14
126	126	fer of value of a type described in section 15
127	127	1128G(a)(1)(A)(vi) of the Social Security Act from a man-16
128	128	ufacturer of a drug (including a biological product) or de-17
129	129	vice that would be required to be disclosed pursuant to 18
130	130	section 1128G(a)(1) of the Social Security Act, if the indi-19
131	131	vidual or organization were a covered recipient or if such 20
132	132	disclosure were required upon request of or by designation 21
133	133	on behalf of a covered recipient pursuant to such section, 22
134	134	the individual or organization shall disclose to the Sec-23
135	135	retary information regarding such payment or other trans-24
136	136	VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\S2922.IS S2922
137	137	kjohnson on DSK7ZCZBW3PROD with $$_JOB 6
138	138	•S 2922 IS
139	139	fer of value. The Secretary shall make such disclosures 1
140	140	publicly available. 2
141	141	‘‘(d) R
142	142	EPORT.—Not later than 2 years after the date 3
143	143	of the enactment of the Advancing Research for Chronic 4
144	144	Pain Act of 2023, the Secretary shall submit a report to 5
145	145	Congress concerning the implementation of this section. 6
146	146	Such report shall include information on— 7
147	147	‘‘(1) the development and maintenance of the 8
148	148	Chronic Pain Information Hub; 9
149	149	‘‘(2) the information made available through 10
150	150	the Chronic Pain Information Hub; 11
151	151	‘‘(3) the data gaps identified, and planned ef-12
152	152	forts to address such gaps; 13
153	153	‘‘(4) the process established for soliciting feed-14
154	154	back from collaborators; and 15
155	155	‘‘(5) feedback received from collaborators. 16
156	156	‘‘(e) D
157	157	EFINITION.—In this section, the term ‘chronic 17
158	158	pain’ means persistent or recurrent pain lasting longer 18
159	159	than 3 months. 19
160	160	‘‘(f) A
161	161	UTHORIZATION OF APPROPRIATIONS.—To 20
162	162	carry out this section, there is authorized to be appro-21
163	163	priated such sums as may be necessary for each of fiscal 22
164	164	years 2024 through 2028.’’. 23
165	165	Æ
166	166	VerDate Sep 11 2014 01:52 Sep 27, 2023 Jkt 039200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6301 E:\BILLS\S2922.IS S2922
167	167	kjohnson on DSK7ZCZBW3PROD with $$_JOB